Vosaroxin: a novel antineoplastic quinolone

Bibliography

• Jameson R, Swinney J. A clinical trial of the treatment of gram-negative urinary infections with nalidixic acid. Br J Urol 1964;35:122-4
   Google Scholar
• Kresse H, Belsey MJ, Rovini H. The antibacterial drugs market. Nat Rev Drug Discov 2007;6(1):19-20
   PubMed Web of Science ®Google Scholar
• Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009;9(5):327-37
   PubMed Web of Science ®Google Scholar
• Drlica K, Malik M, Kerns RJ, Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008;52(2):385-92
   PubMed Web of Science ®Google Scholar
• Waring MJ. DNA modification and cancer. Annu Rev Biochem 1981;50:159-92
   PubMed Web of Science ®Google Scholar
• Liu LF, Rowe TC, Yang L, Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 1983;258(24):15365-70
   PubMedGoogle Scholar
• Chen GL, Yang L, Rowe TC, Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259(21):13560-6
   PubMedGoogle Scholar
• Robinson MJ, Martin BA, Gootz TD, Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 1991;266(22):14585-92
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Ashizawa T, Morimoto M, Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 1992;52(10):2818-22
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Martin BA, Gootz TD Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: influence of the C-8 fluorine group. Antimicrob Agents Chemother 1992;36(4):751-6
   PubMed Web of Science ®Google Scholar
• Okada T, Ezumi K, Yamakawa M, Quantitative structure-activity relationships of antibacterial agents, 7-heterocyclic amine substituted 1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acids. Chem Pharm Bull (Tokyo) 1993;41(1):126-31
   PubMed Web of Science ®Google Scholar
• Wentland MP, Chu DT, Hallas R, Tanaka SK Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives. J Med Chem 1993;36(19):2801-9
   PubMed Web of Science ®Google Scholar
• Chu DT, Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents. Drugs Exp Clin Res 1994;20(5):177-83
   PubMedGoogle Scholar
• Permana PA, Snapka RM, Shen LL, Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 1994;33(37):11333-9
   PubMed Web of Science ®Google Scholar
• Tomita K, Tsuzuki Y, Shibamori K, Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1. J Med Chem 2002;45(25):5564-75
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Sato Y, Synthesis and structure-activity relationships of 3-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines as novel antitumor agents. Bioorg Med Chem Lett 2004;14(12):3189-93
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Tomita K, Shibamori K, Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem 2004;47(8):2097-109
   PubMed Web of Science ®Google Scholar
• Stockett D, Byl JA, Hawtin R, SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning. Proc Am Assoc Cancer Res 2008; Apr 12-16 San Diego, CA:Abstract 1859
   Google Scholar
• Byl JA, Hawtin R, Fox J, Voreloxin as a topoisomerase II poison. Proc Am Assoc Cancer Res 2009; Apr 18-22 Denver, CO:Abstract 1694
   Google Scholar
• Hawtin RE, Stockett DE, Byl JA, Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.. PLoS One 2010; 5(4): p. e10186
   Google Scholar
• Hawtin RE, Stockett D, Lundin C, Voreloxin is active in breast cancer biopsies and potency is enhanced in a BRCA2 mutant background. Proc Am Assoc Cancer Res; Denver, CO. Philadelphia (PA); 2009 [abstract 1708]
   Google Scholar
• Hawtin RE, Stockett DE, Wong OK, . Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010;1(7): p.606-19
   Google Scholar
• Hoch U, Lynch J, Sato Y, . Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009;64(1): p.53-65.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Jonveaux P, Quiquandon I, P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991;78(7):1652-7
   PubMed Web of Science ®Google Scholar
• Wattel E, Preudhomme C, Hecquet B, p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84(9):3148-57
   PubMed Web of Science ®Google Scholar
• Law JC, Ritke MK, Yalowich JC Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 1993;17(12):1045-50
   PubMed Web of Science ®Google Scholar
• Walsby EJ, Coles SJ, Knapper S, The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011;96(3):393-9
   PubMed Web of Science ®Google Scholar
• Scatena CD, Kumer JL, Arbitrario JP, Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.Cancer Chemother Pharmacol 2010;66(5): p.881-8
   Web of Science ®Google Scholar
• Renneville A, Roumier C, Biggio V, Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008;22(5):915-31
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116(24):5089-102
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004;104(4):1145-50
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Synold TW, Somlo G, Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 2001;97(9):2839-45
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339(13):900-5
   PubMed Web of Science ®Google Scholar
• Yeh ET, Tong AT, Lenihan DJ, Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109(25):3122-31
   PubMed Web of Science ®Google Scholar
• Advani RH, Hurwitz HI, Gordon MS, Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res 2010;16(7):2167-75
   PubMed Web of Science ®Google Scholar
• Lancet JE, Karp J, Cripe L, Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients [abstract 7005]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2009
   Google Scholar
• Lancet JE, Roboz GJ, Cripe LD, Phase Ib/2 pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory acute myeloid leukemia patients [abstract 635]. American Society of Hematology (ASH) Annual Meeting; 2009
   Google Scholar
• Lancet JE, Karp J, Cripe L, Voreloxin (formerly known as SNS-595) in combination with cytarabine demonstrates preliminary clinical response in a phase 1 study in relapsed/refractory acute myeloid leukemia [abstract 1955]. American Society of Hematology (ASH) Annual Meeting; 2008
   Google Scholar
• Hoch U, Evanchik MJ, Silverman JA. CYP450 inhibition, induction, metabolism, and routes of elimination of SNS-595, a novel cell cycle inhibitor currently in phase I clinical trials. International Conference on Molecular Targets and Cancer Theraputics: Discovery, Biology, and Clinical Applications. 2005; Philadelphia, PA;Abstract 221
   Google Scholar
• Evanchik MJ, Allen D, Yoburn JC, Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos 2009;37(3):594-601
   PubMed Web of Science ®Google Scholar
• Lancet JE, Ravandi F, Ricklis RM, A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia 2011;25(12):1808-14
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, . Cancer statistics. CA Cancer J Clin 2010;60(5):p.277-300
   Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TETsekov H, Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24(34):5441-7
   PubMed Web of Science ®Google Scholar
• Krug LM, Crawford J, Ettinger DS, Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol 2011;6(2):384-6
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of theproblem. Best Pract Res Clin Obstet Gynaecol 2006;20(2):p.207-25
   Web of Science ®Google Scholar
• Rose PG, Blessing JA, Mayer AR, Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16(2):405-10
   PubMed Web of Science ®Google Scholar
• Markman M, Hall J, Spitz D, Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20(9):2365-9
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Alvarez AA, Sayer RA, Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol 2003;88(1):51-7
   PubMed Web of Science ®Google Scholar
• Rose PG, Mossbruger K, Fusco N, Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003;88(1):17-21
   PubMed Web of Science ®Google Scholar
• Hirte HW, McGuire WP, Edwards R, Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer [abstract 5002]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2010
   Google Scholar
• Hirte HW, McGuire III WP, Edwards RP, . A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. American Society of Clinical Oncology (ASCO) 2009 Annual Meeting Abstract 5559
   Google Scholar
• Sant M, Allemani C, Tereanu C, Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116(19):3724-34
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell O, Wiernik P Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60(2):454-62
   PubMed Web of Science ®Google Scholar
• Projections of the Population by Age and Sex for the United States: 2010 to 2050, U.S.C.B. Population Division, Editor. 2008
   Google Scholar
• Roboz GJ, Lancet JE, Cripe LD, Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed ore refractory acute myeloid leukemia [abstract 6526]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2010
   Google Scholar
• Litzow MR, Othus M, Cripe LD, Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2010;148(2):217-25
   PubMed Web of Science ®Google Scholar
• Maris MB, Kashani F, Stuart R, A phase II study of voerloxin as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia (AML) [abstract 7048]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2009
   Google Scholar
• Ravandi F, Kantarjian HM, Cripe LD, A phase 2 dose regimen optimization study of three schedules of voreloxin as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia [abstract 1037]. American Society of Hematology (ASH) Annual Meeting; 2009
   Google Scholar
• Stuart RK, Kashani FR, Cripe LD, Voreloxin single-agent treatment for older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules [abstract 6525]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2010
   Google Scholar
• Del Poeta G, Stasi R, Aronica G, Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87(5):1997-2004
   PubMed Web of Science ®Google Scholar
• List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996;10(6):937-42
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov; N
   Google Scholar
• Mehta C, Michelson G, Salganik M, Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia [abstract TPS201]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2011
   Google Scholar